EC Gynaecology

Regarding COVID-19, infections caused by RNA Coronaviruses, which are part of the Coronaviridae family, are susceptible to genetic modifications and mutations will continue to form a critical global health threat. The manufacture of vaccines for viral diseases and drug creation is difficult and time-consuming. Because of the disease’s uncertain pathogenesis, the lack of a validated animal model and the success of human clinical trials, the process is much more complex in the case of COVID-19 disease. Vaccines teach the immune system how to detect and activate defense lines against disease-causing microorganisms such as bacteria and viruses. This narrative review aims to present and summarize the literature review investigating the knowledge, attitude and practice towards COVID-19 vaccination in Saudi Arabia. This review demonstrated low levels of knowledge and attitudes among the Saudi population towards the COVID-19 vaccination, which implies poor intentions to vaccinate. Moreover, the healthcare workers also recorded poor knowledge and negative attitudes

Keywords: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); World Health Organization (WHO); Coronavirus Disease 2019 (COVID-19)

1. Wang C., et al. “A novel coronavirus outbreak of global health concern”. The Lancet 395.10223 (2020): 470-473.
2. WHO. The World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it (2021).
3. WHO. World Health Organization Director-General’s Opening Remarks at the Media Briefing on COVID-19–11 (2021).
4. Amawi H., et al. “COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics”. Therapeutic Delivery 11.4 (2020): 245-268.
5. Yi Y., et al. “COVID-19: what has been learned and to be learned about the novel coronavirus disease”. International Journal of Biological Sciences 16.10 (2020): 1753.
6. Mukherjee R. “Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus”. Journal of Biosciences 45 (2020): 1-0.
7. Calina D., et al. “Towards effective COVID 19 vaccines: Updates, perspectives and challenges”. International Journal of Molecular Medicine 46.1 (2020): 3-16.
8. Le TT., et al. “The COVID-19 vaccine development landscape”. Nature Reviews Drug Discovery 19.5 (2020): 305-306.
9. Wouters-Wesseling W., et al. “Effect of a complete nutritional supplement on antibody response to influenza vaccine in elderly people”. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57.9 (2002): M563-566.
10. Alshammari TM., et al. “Importance of early precautionary actions in avoiding the spread of COVID-19: Saudi Arabia as an Example”. Saudi Pharmaceutical Journal 28.7 (2020): 898-902.
11. Lurie N., et al. “Developing Covid-19 vaccines at pandemic speed”. New England Journal of Medicine 382.21 (2020): 1969-1973.
12. Wibawa T. “COVID‐19 vaccine research and development: ethical issues”. Tropical Medicine and International Health 26.1 (2021): 14-19.
13. Pardi N., et al. “mRNA vaccines—a new era in vaccinology”. Nature Reviews Drug Discovery 17.4 (2018): 261.
14. Jackson LA., et al. “An mRNA vaccine against SARS-CoV-2—preliminary report”. New England Journal of Medicine (2020).
15. The New York Time. Coronavirus Vaccine Tracker (2020).
16. Kurupati R., et al. “Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct prevaccination gene expression profiles in blood”. Oncotarget 7.39 (2016): 62898.
17. Angwenyi V., et al. “Health providers’ perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso”. PloS one 10.5 (2015): e0124554.
18. Qattan A., et al. “Acceptability of a COVID-19 Vaccine Among Healthcare Workers in the Kingdom of Saudi Arabia”. Frontiers in Medicine 8 (2021): 83.
19. Barry M., et al. “COVID-19 vaccine confidence and hesitancy among healthcare workers: a cross-sectional survey from a MERS-CoV experienced nation”. Med Rxiv (2020).
20. Al-Mohaithef M and Padhi BK. “Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey”. Journal of Multidisciplinary Healthcare 13 (2020): 1657.
21. Padhi BK and Al-Mohaithef M. “Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey”. Med Rxiv (2020).
22. Alfageeh EI., et al. “Acceptability of a COVID-19 Vaccine among the Saudi Population”. Vaccines 9.3 (2021): 226.
23. Ahmed G., et al. “Healthcare Provider Attitudes toward the Newly Developed COVID-19 Vaccine: Cross-Sectional Study”. Nursing Reports 11.1 (2021): 187-194.
24. Sallam M., et al. “High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries”. Vaccines 9.1 (2021): 42.
25. Magadmi RM and Kamel FO. “Beliefs and Barriers Associated with COVID-19 Vaccination Among the General Population in Saudi Arabia (2020).
26. Felemban RM., et al. “The willingness of the Saudi Arabian population to participate in the COVID-19 vaccine trial: A case–control study”. Journal of Taibah University Medical Sciences (2021).